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Introduction
Esophageal cancer is a cancer with poor prognosis, with an average 5-year survival rate less than 25%. 1 Locally advanced esophageal carcinoma is known to be refractory to treatment of a single modality. Patients with unresectable or medically inoperable disease are usually treated with concurrent radiotherapy and chemotherapy for preoperative or definitive treatment. [2] [3] [4] Although various chemotherapy regimens are available, esophageal cancer carries a very poor prognosis, with a mean survival time of less than 8.1 months. 5 Currently, neoadjuvant treatment (such as capecitabine and cisplatin with concurrent radiotherapy (RT) followed by esophagectomy) is considered the effective treatment for esophageal cancer, 6, 7 leading to complete pathologic response at the time of surgical resection and improved local tumor control and eradication of micrometastases. 8 Clearly, the development of novel and potent therapeutics in/not in combination with RT to improve both local and distant tumor control in esophageal cancer is an urgent task.
External beam radiotherapy (EBRT) is the most commonly used modality of RT for local control of cancer. EBRT can deliver high-energy radiation beams to cover both gross tumors and potential microscopic tumor cells in the vicinity of a tumor. Radionuclide therapy (RNT), another form of RT using radioisotopes emitting short-distance radiation, can directly destroy local and systemic gross tumors inside the torso. 9 RNT uses radiolabeled molecules referred to as "therapeutic radiopharmaceuticals" and is a unique treatment modality lying between chemotherapy and EBRT. The goal of RNT is to kill tumor cells selectively by delivering high radiation doses to a specific target while minimizing damage to normal cells. 9 These carriers include nanoparticles, liposomes, and water-soluble polymers to aid radioisotopes to selectively target and accumulate at cancer sites, thereby improving cancer detection and therapeutic effectiveness. 10 Rhenium-188 ( 188 Re) is a radionuclide designed for dual imaging and therapeutic applications because of its short physical half-life of 16.9 hours with 155 keV gamma emission (for molecular imaging) and 2.12 MeV emission (for therapeutic RT) and a maximum tissue penetration range of 11 mm. 11 The high efficiency, stability, and convenience of 188 Re-liposome have been demonstrated in the treatment of cancer. 12 Although 188 Re-liposome and radiochemotherapeutic drugs, for example, 188 Re-doxorubicin-liposome, have been studied in many experiments, the application potential of 188 Re-liposome in cancer therapy remains to be developed. [13] [14] [15] [16] [17] Our previous studies have investigated the biodistribution, pharmacokinetics, and NanoSPECT/CT imaging after systematic administration of Re-liposome by intraperitoneal and intravenous injection methods in colon carcinoma ascites and solid-tumor animal models. 13 Re-liposome has a comparative therapeutic efficacy with chemotherapeutic drug 5-FU in colon carcinoma ascites, we found that 188 Re-liposome possesses a better therapeutic efficacy in both lung-metastatic and solid-tumor animal models. 18, [20] [21] [22] No documents using 188
Re-liposome as RNT or RNT combined with EBRT to assess the therapeutic efficacy in esophageal cancer have been published yet. EBRT combined with RNT may enhance the cytotoxicity in tumor cells and reduce normal tissue damage, using the advantages of conformal EBRT and the selective targeting of tumors using RNT. The efficacy and radiation dose of EBRT or RNT alone and EBRT combined with RNT have not been determined yet. It is important to clarify the difference in characteristics between EBRT and RNT, and the impact on the combination of EBRT and RNT.
In the present study, we examined the combinatory effect of EBRT and 188 Re-liposome for treatment of esophageal cancer. The impact of EBRT on the biodistribution of 188 Reliposome was also assessed.
Materials and methods

Xenografts of esophageal cancer
Human esophageal cancer cell lines, CE81T/VGH (squamous cell carcinoma) and BE-3 (adenocarcinoma) cells, were kindly provided by Professor Hu (Veteran's General Hospital, Taipei, Taiwan) and purchased from the American Type Culture Collection (Manassas, VA, USA), respectively. These two esophageal cancer cell lines were maintained in DMEM (Dulbecco's Modified Eagle's Medium) (GIBCO BRL, Grand Island, NY, USA) supplemented with NaHCO 3 (10 mmol/L), HEPES (20 mmol/L), 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT, USA), 2 mM L-glutamine, 1 mM nonessential amino acid, and 1 mM sodium pyruvate and incubated at 37°C in 5% CO 2 . Fourweek-old, male BALB/c nude mice were obtained from the National Laboratory Animal Center of Taiwan (Taipei, Taiwan) and bred in a specific pathogen-free animal facility. 
Preparation and characterization of 188 re-liposome
Pegylated liposomes (Nano-X, Taiwan Liposome Company, Taipei, Taiwan) were prepared according to the method described by Tseng et al. 23 The lipid composition of liposomes contains hydrogen soybean phosphatidylchloine (HSPC), cholesterol, polyethylene glycol (1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine, PEG-DSPE; molar ratio 3:2:0.3), and ammonium sulfate solution with 250 mM (NH 4 ) 2 SO 4 , pH 5.0 in the inner water phase. Pegylated nanoliposomes have an average particle size of approximately 82.59 nm and contain 13.16 μmol/mL phospholipids. The labeling method of 188 Reliposome was as previously described. 13, 14 Prior to labeling, Re-BMEDA was adjusted to a pH of 7.0 with 2 N NaOH. Nano-X pegylated liposomes were added to 188 Re-BMEDA and incubated at 60°C for 30 minutes to form 188 Re-BMEDA-liposome complexes. The 188 Re-liposomes were separated from free 188 Re-BMEDA using a PD-10 column (GE Healthcare, Piscataway, NJ, USA) and eluted with normal saline. The encapsulation efficiency was determined using the activity in pegylated liposomes after separation divided by the total activity before separation.
Delivery of external beam radiotherapy and combinatory regimen
Before irradiation, tumor-bearing mice were anesthetized by intramuscular injections of ketamine (100 mg/kg)/xylazine (10 mg/kg body weight). EBRT with a 6 MeV electron beam was delivered by a linear accelerator (Clinac 1800, Varian Associates, Inc., Palo Alto, CA, USA) with a dose rate of 2.4 Gy/min and, locally, irradiation was performed within tumor region (right hind limb). Before the combination of EBRT and RNT, optimal dosage of each treatment was estimated to suppress less than 50% of tumor growth (3 Gy for ERBT and 13.3 MBq [360 μCi] for RNT, data not shown). After 2 hours of transport time, RNT was performed by intravenous injection of 188 Re-liposome.
NanosPecT/cT analysis
Tumor-bearing mice were intravenously injected with 18.5 MBq (500 μCi) of 188
Re-liposome, and images were acquired using the NanoSPECT/CT scanner system (NanoSPECT/CT PLUS, Mediso, Alsotorokvesz, Budapest, Hungary). Before scanning, mice were anesthetized with 1.5% isoflurane, and NanoSPECT/CT imaging was performed at 1, 4, and 24 hours after injection of 188 Re-liposome. The imaging acquisition was accomplished using 70 frames at 40 seconds per frame, and the energy windows were 155 keV ±20% and 64 keV ±20%. The SPECT imaging was followed by CT image acquisition with the animal in exactly the same position (X-ray source: 45 kV, 0.1 mA; 180 projections). For image reconstruction, HiSPECT and Nucline software were used for the SPECT and CT images, respectively. The InVivoScrope software was used for the fusion of SPECT and CT images. 
Tumor growth evaluation
Fourteen days after inoculation, tumor-bearing mice were divided randomly into five groups with five mice per group, and two groups (injected with normal saline or with liposomes) were used as the controls. The other three groups of mice were treated with EBRT (ionizing radiation, 3 Gy), RNT Re-liposome). Tumor size was recorded twice a week using a caliper to measure tumor growth, and tumor volumes were estimated according to the formula 0.5ab 2 , where a is the largest and b is the smallest perpendicular diameter. 24 The tumor growth delay was defined as the subtraction of days required for three fold tumor volume growth between treated and untreated groups.
Toxicity assessment
Toxicity was monitored twice a week by the changes in mouse weight and immunological and hematological indicators. Immunological toxicity was observed from the counts of white blood cells (WBC) using the retro-orbital blood sampling method in a Hemavet blood analyzer (Drew Scientific, Oxford, CT). Hematological toxicities were examined by the detection of alanine aminotransferase (ALT) and creatinine (CRE), measuring the functions of liver and kidneys, respectively. The level of ALT and CRE were freshly measured by a Fuji Dri-Chem 3500 machine (Fujifilm Medical System, Tokyo, Japan). 
Results
Labeling efficiency of 188 re-liposome
The labeling efficiency of 188 Re and BMEDA was measured by instant thin-layer chromatography on silica gelimpregnated glass fiber sheets (ITLC-SG), and the result showed that the purity of 188 Re-BMEDA was 96.7%±5.8% (Figure 1) , as the radioactivity complex ( 188 Re-BMEDA) remained at the origin ( Figure 1B) , whereas free 188 Re migrated in the strip ( Figure 1A ). The encapsulation efficiency of 188 Re-BMEDA-liposome was 65.7%±1.6%, and the radiochemical purity of 188 Re-liposome exceeded 95% after purification with PD-10 columns. The average particle size of 188 Re-liposome was similar to that before 188 Re-BMEDA encapsulation.
NanosPecT/cT imaging of 188 re-liposome
To discriminate the uptake of 188 Re-liposome in two major cell types of esophageal cancer, we examined the uptake of Re-liposome excretion, dose-dependent irradiation (3, 6, 9 Gy) was delivered to BE-3 tumor xenografts followed by 188 Re-liposome intravenous injection (Figure 3) . The result confirmed that the fecal excretion of 188 Re-liposome was significantly enhanced by irradiation without significant influence on the uptake of Re-liposome at the experimental dosage, no significant abnormality in the hemogram and biochemistry profile were noted, indicating 
Discussion
The current standard of treatment for locally advanced or unresectable esophageal cancer is concurrent chemoradiation therapy (CCRT). The long-term results of RTOG 85-01 trials show a survival benefit of CCRT in comparison with RT alone. 25 Van Hagen et al 26 found neoadjuvant chemoradiotherapy improved overall survival of patients with resectable esophageal cancer compared to the group with surgery alone. The most common toxic effects after CCRT were leukopenia (6%), neutropenia (2%), anorexia (5%), and fatigue (3%). Bass et al 27 revealed that neoadjuvant chemoradiotherapy significantly provided survival advantage and risk reduction in lymph-node metastasis over surgical monotherapy for patients with esophageal adenocarcinoma. These reports supported that CCRT could be the definitive treatment or a neoadjuvant treatment prior to major surgery. However, the 5-year survival rate of locally advanced esophageal cancer remains less than 30% after aggressive treatment by CCRT. 28 The persistence of local disease was the greatest cause of treatment failures. 2 To address this clinical issue in a translational research model, we demonstrated better tumor control by using a combination of EBRT and 188 Re-liposome against primary tumors. The major pattern of failure for treatment of esophageal cancer is local recurrence and distant metastasis. Thus, the next clinical issue to be examined is the effect of this combination regimen on the distant metastasis of esophageal cancer in experimental animal models.
Nanocarrier delivery systems have been shown to have enhanced imaging and therapeutic efficacy by targeted delivery of drugs to the tumor site and by reducing their toxic side effects. [29] [30] [31] Major advantages of nanocarriers are that they can be prepared in sizes 100 nm and ensuring minimal drug or radionuclide leaking out from the carriers during circulation to enhance passive targeting and to increase the localization of drugs and radionuclides in the tumor through enhanced permeability and retention (EPR) effect to the leaky tumor tissues, and nanoliposomes have been widely studied as an important carrier in controlling the localization and concentration of drugs to improve the pharmaceutical and therapeutic properties of drug administration by EPR effect. 32, 33 Pegylated liposomes can evade the reticuloendothelial system and remain in the circulatory system for prolonged periods, resulting in sufficient tumor targeting and efficacy in vivo. 34, 35 External beam radiation has been reported as a method that enhances nanoliposome uptake in the tumor region due to radiation-induced inflammation. 36 The increased uptake of nanoliposomes was detected at 24 hours following external beam radiation. The result suggests that combining modality therapy with external beam radiation and nanoliposome chemotherapy may be more effective for the treatment of tumors than administering these therapies sequentially. 36 In our study, the effect of EBRT on the accumulation of 188 Re-liposome in tumors was not found to be statistically significant (Table 1) . It might be due to the deficiency of the Re-liposome, which may be too short to enhance permeability and retention. Since the combination of EBRT and 188 Re-liposome increased therapeutic efficacy compared to EBRT and 188 Re-liposome treatment alone, the uptake of 188 Re-liposome on esophageal adenocarcinoma BE-3 cells is likely to play a role in enhancing radiation-induced toxicity. Further investigation will need to be done to confirm or refute these findings. The effect of EBRT on the biodistribution of 188 Re-liposome in this study, especially on the secretion of isotopes into urine and feces, is unique. It may indicate a better secretion profile after treatment. Whether this effect would damage the lower urinary tract or the lower gastrointestinal tract remains to be elucidated.
To control local tumors, regional lymphatics, and distant metastasis simultaneously, our design was to combine EBRT and 188 Re-liposome for the treatment of esophageal cancer, a malignancy with a high risk of recurrence and metastasis. Our results indicate that the combinatory regimen may have additive effects against the growth of human esophageal adenocarcinoma xenografts without an increase in toxicity ( Figure 5 ).
Conclusion
In this study, it was found that human esophageal adenocarcinoma BE-3 cells, but not squamous cell carcinoma CE81T/VGH, showed specific uptake of 188 Re-liposome. The 188 Re-liposome combined with EBRT could have therapeutic efficacy on tumor growth control in BE-3 cells and 188 Re-liposome might be a potential treatment modality for esophageal cancer by enabling molecular imaging, image-guided treatment, and comprehensive radiation therapy coverage simultaneously.
